专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07598228B2 Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1 失效
标题翻译：与AOP-1基因或AOP-1表达降低相关的疾病的治疗方法和药剂
公开(公告)号：US07598228B2
公开(公告)日：2009-10-06
申请号：US10642272
申请日：2003-08-18
申请人： Fumiyuki Hattori , Keijiro Sugimura , Mayumi Furuya
发明人： Fumiyuki Hattori , Keijiro Sugimura , Mayumi Furuya
IPC分类号： A61K48/00 , A01N63/00
CPC分类号： A61K48/005 , A61K31/711 , A61K38/00 , A61K48/00 , C12N9/0089 , C12N2799/022 , C12N2799/04 , G01N33/576 , G01N33/6893 , G01N2500/00 , G01N2800/085 , G01N2800/102 , G01N2800/2842 , G01N2800/325 , G01N2800/347
摘要： A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid sequence of AOP-1 while retaining the function of AOP-1, or (2) administering a material enhancing the expression of AOP-1 gene, a material enhancing the production of AOP-1 or a material enhancing the function of AOP-1.
摘要翻译：一种与AOP-1基因或AOP-1表达降低相关的疾病的预防或治疗方法，包括（1）转染编码AOP-1的核酸或编码具有添加，缺失或取代的多肽的核酸或更多的氨基酸与AOP-1的氨基酸序列相比较，同时保留AOP-1的功能，或（2）施用增强AOP-1基因表达的材料，一种增强AOP-1功能的材料。

2. 发明申请

US20050277606A1 Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1 失效
标题翻译：与AOP-1基因或AOP-1表达降低相关的疾病的治疗方法和药剂
公开(公告)号：US20050277606A1
公开(公告)日：2005-12-15
申请号：US10642272
申请日：2003-08-18
申请人： Fumiyuki Hattori , Keijiro Sugimura , Mayumi Furuya
发明人： Fumiyuki Hattori , Keijiro Sugimura , Mayumi Furuya
IPC分类号： A61K31/711 , A61K38/00 , A61K38/08 , A61K38/17 , A61K38/44 , A61K48/00 , A61P1/16 , A61P9/02 , A61P9/10 , A61P13/12 , A61P19/02 , A61P25/00 , A61P29/00 , C12N9/02 , G01N33/68
CPC分类号： A61K48/005 , A61K31/711 , A61K38/00 , A61K48/00 , C12N9/0089 , C12N2799/022 , C12N2799/04 , G01N33/576 , G01N33/6893 , G01N2500/00 , G01N2800/085 , G01N2800/102 , G01N2800/2842 , G01N2800/325 , G01N2800/347
摘要： A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid sequence of AOP-1 while retaining the function of AOP-1, or (2) administering a material enhancing the expression of AOP-1 gene, a material enhancing the production of AOP-1 or a material enhancing the function of AOP-1.
摘要翻译：一种与AOP-1基因或AOP-1表达降低相关的疾病的预防或治疗方法，包括（1）转染编码AOP-1的核酸或编码具有添加，缺失或取代的多肽的核酸或更多的氨基酸与AOP-1的氨基酸序列相比较，同时保留AOP-1的功能，或（2）施用增强AOP-1基因表达的材料，一种增强AOP-1功能的材料。

3. 发明授权

US07816511B2 Remedies for heart failure 失效
标题翻译：心力衰竭的补救措施
公开(公告)号：US07816511B2
公开(公告)日：2010-10-19
申请号：US10383241
申请日：2003-07-16
申请人： Kayoko Kawashima , Naruto Katsuragi , Keijiro Sugimura , Mayumi Furuya , Ryuichi Morishita
发明人： Kayoko Kawashima , Naruto Katsuragi , Keijiro Sugimura , Mayumi Furuya , Ryuichi Morishita
IPC分类号： C07H21/04 , A01N43/04 , A61K31/70
CPC分类号： C07K14/475 , A01K2217/05 , A61K39/00 , C07K14/47
摘要： The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.
摘要翻译：本发明提供了筛选抑制OSF-2基因表达的药物的方法或由其编码的蛋白质的产生或功能以及具有这种作用的心力衰竭治疗剂。可以通过监测所述基因的表达或变异或由其编码的蛋白质的产生来提供用于诊断心力衰竭的有用方法。本发明还提供了强力表达OSF-2基因的转基因动物以及用于研究基因表达或蛋白质生产的变化的方法，或者使用它们的心力衰竭病理进展的各种基因或蛋白质的功能和新的治疗剂心脏衰竭。

4. 发明授权

US5434133A CNP analog peptides and their use 失效
标题翻译： CNP类似物及其用途
公开(公告)号：US5434133A
公开(公告)日：1995-07-18
申请号：US828450
申请日：1992-01-31
申请人： Shoji Tanaka , Yoshiharu Minamitake , Yasuo Kitajima , Mayumi Furuya , Hisayuki Matsuo
发明人： Shoji Tanaka , Yoshiharu Minamitake , Yasuo Kitajima , Mayumi Furuya , Hisayuki Matsuo
IPC分类号： A61K38/22 , A61K38/00 , A61P43/00 , C07K7/08 , C07K14/575 , C07K14/58 , C12N15/16 , C07K14/00 , A61K38/16 , A61K38/17 , C07K14/435
CPC分类号： C07K14/58 , A61K38/00 , Y02P20/55
摘要： Novel peptides represented by the general formula: ##STR1## and physiologically acceptable acid addition salts thereof; where (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, H-Ser-Leu-Arg-Arg-Ser-Ser;(B) represents H-Cys or Pmp;(C) represents Phe-, pCl-Phe, pF-Phe, pNO.sub.2 -Phe or Cha;(D) represents Ile, Val, Aib, tLeu, Gly or Leu;(E) represents Lys or Arg;(F) represents Ile, Leu or Met;(G) represents Ser or Ala;(H) represents Met or Gln;(I) represents --OH, -Asn-OH, -Asn-Ser-OH, -Asn-Ser-Phe-OH, -Asn-Ser-Phe-Arg-OH or -Asn-Ser-Phe-Arg-Tyr-OH; and the symbol " . . . " represents a disulfide bond;provided that 1) .alpha.-hANP, 2) .alpha.-hANP (7-28) and 3) CNP-22 are excluded from the scope of that general formula.Also disclosed are agents for suppressing the growth of vascular smooth muscle cells that contains those peptides as effective ingredients.
摘要翻译：由通式表示的新肽：其加成盐; 其中（A）表示H，H-Gly，H-Lys-Gly，H-Ser-Lys-Gly，H-Leu-Ser-Lys-Gly，H-Gly-Leu-Ser-Lys-Gly， Ser，H-Ser-Ser，H-Arg-Ser-Ser，H-Arg-Arg-Ser-Ser，H-Leu-Arg-Arg-Ser-Ser，H-Ser-Leu-Arg-Arg- 塞尔（B）代表H-Cys或Pmp; （C）表示Phe-，pCl-Phe，pF-Phe，pNO2-Phe或Cha; （D）代表Ile，Val，Aib，tLeu，Gly或Leu; （E）表示Lys或Arg; （F）表示Ile，Leu或Met; （G）表示Ser或Ala; （H）表示Met或Gln; （I）表示-OH，-Asn-OH，-Asn-Ser-OH，-Asn-Ser-Phe-OH，-Asn-Ser-Phe-Arg-OH或-Asn-Ser-Phe-Arg-Tyr- 哦; 符号“......”代表二硫键; 条件是1）α-hANP，2）α-hANP（7-28）和3）CNP-22被排除在该通式的范围之外。还公开了抑制含有那些肽作为有效成分的血管平滑肌细胞生长的药剂。

5. 发明授权

US09233143B2 Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists 有权
标题翻译：用于预防恶性肿瘤恶化的药物，包括利钠肽受体GC-A和GC-B激动剂的组合
公开(公告)号：US09233143B2
公开(公告)日：2016-01-12
申请号：US14239301
申请日：2012-08-17
申请人： Kenji Kangawa , Hiroshi Hosoda , Takashi Nojiri , Meinoshin Okumura , Mayumi Furuya
发明人： Kenji Kangawa , Hiroshi Hosoda , Takashi Nojiri , Meinoshin Okumura , Mayumi Furuya
IPC分类号： A61K38/22 , A61K45/06
CPC分类号： A61K38/22 , A61K38/2242 , A61K45/06 , A61K2300/00
摘要： Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.
摘要翻译：本发明提供作为恶性肿瘤的治疗高度安全的药剂，能够有效治疗恶性肿瘤，即用于治疗恶性肿瘤的药剂或抑制或预防恶化肿瘤的药物，其包含：至少一种利尿钠肽受体GC-A激动剂和至少一种利钠肽受体GC-B激动剂组合施用; 一种治疗方法，包括施用所述药剂; 等等

6. 发明申请

US20140248269A1 MEDICINAL AGENT FOR PREVENTING EXACERBATION OF MALIGNANT TUMOR, COMPRISING COMBINATION OF NATRIURETIC PEPTIDE RECEPTOR GC-A AND GC-B AGONISTS 有权
标题翻译：用于预防恶性肿瘤发生的药物，包含NATRIURETIC PEPTIDE RECEPTOR GC-A和GC-B激动剂的组合
公开(公告)号：US20140248269A1
公开(公告)日：2014-09-04
申请号：US14239301
申请日：2012-08-17
申请人： Kenji Kangawa , Hiroshi Hosada , Takashi Nojiri , Meinoshin Okumura , Mayumi Furuya
发明人： Kenji Kangawa , Hiroshi Hosada , Takashi Nojiri , Meinoshin Okumura , Mayumi Furuya
IPC分类号： A61K38/22 , A61K45/06
CPC分类号： A61K38/22 , A61K38/2242 , A61K45/06 , A61K2300/00
摘要： Provided are a medicinal agent which is highly safe for use as the treatment of a malignant tumor and is capable of efficiently treating a malignant tumor, that is, a medicinal agent for treating a malignant tumor or for suppressing or preventing the exacerbation thereof, comprising at least one kind of natriuretic peptide receptor GC-A agonist and at least one kind of natriuretic peptide receptor GC-B agonist to be administered in combination; a therapeutic method comprising administering the agent; etc.
摘要翻译：本发明提供作为恶性肿瘤的治疗高度安全的药剂，能够有效治疗恶性肿瘤，即用于治疗恶性肿瘤的药剂或抑制或预防恶化肿瘤的药物，其包含：至少一种利尿钠肽受体GC-A激动剂和至少一种利钠肽受体GC-B激动剂组合施用; 一种治疗方法，包括施用所述药剂; 等等

7. 发明授权

US06544604B2 Liquid crystalline compound having difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element 有权
标题翻译：具有二氟亚丙氧基作为键合基团的液晶化合物，液晶组合物和液晶显示元件
公开(公告)号：US06544604B2
公开(公告)日：2003-04-08
申请号：US09925484
申请日：2001-08-10
申请人： Shuichi Matsui , Yasuyuki Sasada , Kazutoshi Miyazawa , Hiroyuki Takeuchi , Katsuyuki Kawano , Yasuhiro Kubo , Etsuo Nakagawa , Mayumi Furuya
发明人： Shuichi Matsui , Yasuyuki Sasada , Kazutoshi Miyazawa , Hiroyuki Takeuchi , Katsuyuki Kawano , Yasuhiro Kubo , Etsuo Nakagawa , Mayumi Furuya
IPC分类号： C09K1934
CPC分类号： C09K19/46 , C09K19/20 , C09K19/3001 , C09K19/3066 , C09K19/42 , C09K19/44 , C09K2019/0448 , C09K2019/0451 , C09K2019/3027 , Y10T428/10
摘要： The present invention provides a liquid crystalline compound having a difluoropropyleneoxy group as a bonding group, which is represented by Formula (1): wherein R1 and R2 each independently represent hydrogen, halogen, a cyano group or an alkyl group having 1 to 20 carbon atoms; rings A1 to A5 each independently represent a 1,4-cyclohexylene group, a 1,4-cyclohexenylene group or a 1,4-phenylene group; Z1 to Z4 each independently represent a single bond, —CH2CH2—, —CH2O—, —OCH2—, —COO—, —OCO—, —CH═CH—, —C≡C—, —CF2O— or —OCF2—; Y1, Y2, Y3 and Y4 each independently represent hydrogen or fluorine; and k, l, m and n each independently represent 0 or 1. This liquid crystalline compound has a large absolute value (|&Dgr;&egr;|) of a dielectric anisotropy and shows a relatively small refractive anisotropy. The present invention further provides a liquid crystal composition comprising this compound which makes it possible to drive display elements of various modes at a low voltage, and a liquid crystal display element containing this liquid crystal composition.
摘要翻译：本发明提供具有二氟亚丙氧基作为键合基团的液晶化合物，其由式（1）表示：其中R 1和R 2各自独立地表示氢，卤素，氰基或具有1至20个碳原子的烷基 ; 环A1至A5各自独立地表示1,4-亚环己基，1,4-亚环己基或1,4-亚苯基; Z 1至Z 4各自独立地表示单键，-CH 2 CH 2 - ， - CH 2 O - ， - OCH 2 - ， - COO - ， - OCO-， - CH = CH-，-C = C - ， - CF 2 O-或-OCF 2 - Y 1，Y 2，Y 3和Y 4各自独立地表示氢或氟; 并且k，l，m和n各自独立地表示0或1.该液晶化合物的介电各向异性的绝对值（| DELTAepsi |）大，折射率各向异性相对较小。本发明还提供一种包含该化合物的液晶组合物，其可以驱动低电压的各种模式的显示元件，以及含有该液晶组合物的液晶显示元件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式